Group 1: Shareholder Pledge and Control - The controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen, accounting for 7.08% of its holdings and 1.78% of the company's total share capital. The freeze period is from January 30, 2026, to January 29, 2029. The company states this will not lead to a change in control and will not have a substantial impact on operations [2]. Group 2: Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -5 million and -3 million yuan, indicating a significant reduction in losses of 97.14% to 98.28% compared to a loss of 175 million yuan in the same period of 2024. This improvement is attributed to lean operations in the medical sector, cost control, and a significant reduction in goodwill impairment [3]. Group 3: Related Party Transactions - The company’s board approved a total of up to 15 million yuan for daily related party transactions with Guangzheng Yanyuan Health Management Co., Ltd. and its subsidiaries for the year 2026 [4]. Group 4: Management Changes - A new senior management team has been appointed, including positions such as Vice President, Chief Financial Officer, and Board Secretary, as of December 28, 2025 [5]. Group 5: Business Development - The company has increased its investment in ophthalmology by acquiring, establishing, and holding stakes in multiple ophthalmology-related companies throughout 2025 [6].

Core Viewpoint - Guangzheng Eye Hospital Group announced that its controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen due to a judicial order, which represents 7.08% of its holdings and 1.78% of the company's total share capital. The freeze is effective from January 30, 2026, to January 29, 2029, and will not affect the company's control or operations significantly [1][2]. Group 1 - Guangzheng Investment's frozen shares amount to 9.15 million, accounting for 7.08% of its total holdings and 1.78% of the company's total share capital [1][2]. - The judicial freeze was initiated by the Dongguan Intermediate People's Court in Guangdong Province [2]. - The company stated that this share freeze will not lead to any change in control and that it maintains independence in assets, business, and finance [2]. Group 2 - Guangzheng Eye Hospital has reported negative net profits for 12 consecutive years from 2013 to 2024, with a projected revenue of 893 million yuan in 2024, a decline of 16.94% year-on-year [3]. - The company expects a net loss of 3 to 5 million yuan for 2025, a significant improvement compared to the previous year's loss of 175 million yuan [3]. - The company plans to enhance operational efficiency through lean management and cost control measures in its medical sector for 2025 [3]. Group 3 - As of February 6, the stock price of Guangzheng Eye Hospital closed at 4.71 yuan per share, with a total market capitalization of 2.427 billion yuan [4].

Core Viewpoint - The shares of Guangzheng Eye Hospital's controlling shareholder, Guangzheng Investment Co., Ltd., have been judicially frozen, affecting 9.1503 million shares, which is 7.08% of the shares held by the shareholder and 1.78% of the company's total share capital [1] Group 1 - The reason for the share freeze is due to judicial actions, with specific details yet to be confirmed [1] - The share freeze will not lead to a change in the company's control [1] - The company maintains independence from its controlling shareholder in terms of assets, business, and financial matters [1] Group 2 - There will be no substantial impact on the company's production operations or governance as a result of the share freeze [1]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-004 光正眼科医院集团股份有限公司 关于控股股东部分股份冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 光正眼科医院集团股份有限公司（以下简称"公司"）于近日通过查询中国 证券登记结算有限责任公司深圳分公司业务系统，获悉公司控股股东光正投资有 限公司（以下简称"光正投资"）所持有的部分股份被司法冻结的情况。具体情 况如下： 质性影响。 | 股东 | 是否为控股 | 本次冻 | 占其所 | 占公司 | 是否为 | 冻结起 | 冻结 | 冻结申 | 原因 | 名称 | 股东或第一 | 结股份 | 持股份 | 总股本 | 限售股 | 始日 | 到期 | 请人 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 大股东及其 | 数量 | 比例 | 比例（%） | ...

Core Viewpoint - Guangzheng Eye Hospital (002524.SZ) forecasts a net profit loss of 3 million to 5 million yuan for the year 2025, a significant improvement compared to a loss of 175 million yuan in the same period last year [1]. Financial Performance Summary - The net profit attributable to shareholders is expected to be between -5 million and -3 million yuan, showing a 97.14% improvement compared to the previous year's loss of 174.65 million yuan [2]. - The net profit after deducting non-recurring gains and losses is projected to be between -18 million and -12 million yuan, reflecting a 90.75% increase from last year's loss of 194.52 million yuan [2]. - Basic earnings per share are estimated at -0.0099 yuan, compared to -0.0050 yuan in the previous year [2].

Market Overview - The medical services sector experienced a decline of 1.64% on January 28, with Guangzheng Eye Care leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Individual Stock Performance - Guangzheng Eye Care (002524) saw a significant drop of 8.63%, closing at 5.08, with a trading volume of 1.41 million shares and a transaction value of 721 million [2] - Other notable declines included Yinuosi (688710) down 7.45% and Haoyuan Pharmaceutical (688131) down 6.49% [2] - In contrast, ST Zhongzhu (600568) increased by 1.43%, closing at 2.83, with a trading volume of 338,300 shares [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 1.697 billion in institutional funds, while retail investors saw a net inflow of 1.544 billion [2] - Notable stocks with significant capital inflow included Sunshine Nuohe (688621) with a net inflow of 27.668 million from institutional investors [3] - Conversely, stocks like ST Zhongzhu (600568) and Wanbang Medical (301520) faced net outflows from institutional investors [3]

Core Viewpoint - Guangzheng Eye Hospital announced that its stock price experienced a cumulative deviation of over 20% on January 26 and January 27, 2026, which meets the criteria for abnormal stock fluctuations set by the Shenzhen Stock Exchange [1]. Group 1 - The stock price fluctuation occurred over two consecutive trading days [1].

Core Viewpoint - The stock of Guangzheng Eye Hospital experienced a significant price fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days, prompting an announcement regarding abnormal stock trading behavior [1] Summary by Relevant Sections - **Stock Price Movement** - The stock price of Guangzheng Eye Hospital rose by more than 20% over two trading days on January 26 and January 27, 2026, indicating a significant deviation from normal trading patterns [1] - **Company Disclosure** - The company confirmed that there are no corrections or supplements needed for previously disclosed information, and no undisclosed significant information has been found that could impact stock trading prices [1] - **Operational Status** - The recent operational situation of the company remains normal, with no significant changes in the internal or external business environment [1] - **Shareholder Activity** - The company, its controlling shareholders, and actual controllers have not engaged in any stock trading activities during the period of abnormal price fluctuation, and there are no undisclosed significant matters [1]

光正眼科医院集团股份有限公司 证券代码：002524 证券简称：光正眼科 公告编号：2026-002 光正眼科医院集团股份有限公司 关于公司股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 光正眼科医院集团股份有限公司(以下简称"公司"或"本公司")股票（证 券简称：光正眼科，证券代码：002524）于 2026 年 1 月 26 日、2026 年 1 月 27 日连续两个交易日收盘价格涨幅偏离值累计超过 20%，符合深圳证券交易所股票 异常波动的相关标准。 二、公司关注并核实的情况说明 针对公司股票交易异常波动的相关情况，公司对相关事项进行核查，并询问 了公司控股股东，现就有关关注问题及核实结论说明如下： 1、公司前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息； 3、公司近期经营情况正常，内外部经营环境未发生重大变化； 4、公司、控股股东、实际控制人不存在关于公司的应披露而未披露的重大 事项； 5、控股股东、实际控制人在 ...

Market Overview - The medical services sector experienced a decline of 1.41% on January 26, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable gainers in the medical services sector included: - Guangzheng Eye Hospital (002524) with a closing price of 5.05, up 10.02% on a trading volume of 266,400 shares and a transaction value of 132 million [1] - Lanwei Medical (301060) closed at 12.28, up 3.98% with a trading volume of 325,000 shares and a transaction value of 392 million [1] - Major decliners included: - Meidisi (688202) closed at 60.88, down 7.28% with a trading volume of 71,600 shares and a transaction value of 444 million [2] - Meinian Health (002044) closed at 7.26, down 6.08% with a trading volume of 3.7675 million shares and a transaction value of 2.776 billion [2] Capital Flow - The medical services sector saw a net outflow of 1.318 billion from institutional investors, while retail investors had a net inflow of 1.011 billion [2] - The capital flow for specific stocks showed: - Boteng Co. (300363) had a net outflow of 39.83 million from institutional investors [3] - Guangzheng Eye Hospital (002524) had a net inflow of 39.29 million from institutional investors [3] - Lanwei Medical (301060) had a net inflow of 24.71 million from institutional investors [3]